Lithium Americas – The Great Prize: NYSE
In similar
Lithium Americas – The Great Prize: NYSE
In similar manner to Born to Run
…straight into the Big Leagues. It announced recently that it sees the benefit of tapping into the much, much larger United States of America investor base through a more sensible stock price and total shares outstanding that is more typical of The New York Stock Exchange, still the World’s Most Prestigious Stock Exchange Brand.
Goodbye: LACDF OTCQX
Hello: LAC NYSE
Mainstream. This makes a difference. More liquidity, less volatility, higher multiples
LAC’s NYSE listing is timely as construction at Cauchari is well underway and LAC’s Lithium Nevada, USA project is expected to come into greater focus.
LAC will soon no longer be seen principally through the junior miner TSX/ASX penny stock lens and lined up mainly against NMX and ORE. Instead, SQM followers will realize through LAC they get pure-play exposure to SQM’s fastest growing, highest margin, longest lived cash flows. Likewise, those who prefer ALB over SQM due to confused Chilean politics, but are learning to love Argentina. And FMC holders already knowledgeable about Hombre Muerto.
Reminder: BTG Pactuel’s Cesar Perez, the analyst with longest history and most gravitas on SQM, values LAC and SQM’s stakes in Minera Exar which operates the Cauchari JV at $2B each or $4B for the whole JV. That $2B is TODAY, based on his DCF model discounting back from 2024 presuming 50K tons and $12K lithium price. $2B is nearly 3 times higher than LAC’s current valuation.
Lithium Americas Corp. (LACDD) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...
Continue Reading
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading